GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » BioDelivery Sciences International Inc (FRA:BD5) » Definitions » Momentum Rank

BioDelivery Sciences International (FRA:BD5) Momentum Rank : 0 (As of May. 28, 2024)


View and export this data going back to 2004. Start your Free Trial

What is BioDelivery Sciences International Momentum Rank?

BioDelivery Sciences International has the Momentum Rank of 0.

For Momentum Rank, we considered the residual momentum concept that was widely studied by Blitz and his colleagues as well as by Nobel Prize laureates Fama and French. However, we did not find any significant differences in the performances of stocks with different ranks of residual momentum. Therefore, we use traditional momentum instead.

Momentum Rank is determined using the standardized momentum ratio and other momentum indicators. The standardized momentum ratio is the average of the performances from 12 months ago to 1 month ago and 6 months ago to 1 month ago, divided by the beta of the stock over the past 12 months. To calculate the momentum ratio today, we would use the average of the two performance numbers.

For momentum, we found that stock price performance does not have a monotonic correlation with the momentum ratio. The stocks with the highest momentum ratios perform worse than those at about the 70th percentile. Therefore, for the momentum rank, we ranked the stocks at about the 70th percentile of the momentum ratio as the highest at 10.

Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.


BioDelivery Sciences International Momentum Rank Related Terms

Thank you for viewing the detailed overview of BioDelivery Sciences International's Momentum Rank provided by GuruFocus.com. Please click on the following links to see related term pages.


BioDelivery Sciences International (FRA:BD5) Business Description

Traded in Other Exchanges
N/A
Address
4131 ParkLake Avenue, Suite 225, Raleigh, NC, USA, 27612
BioDelivery Sciences International Inc is a rapidly growing commercial-stage specialty pharmaceutical company dedicated to patients living with chronic pain. The company is utilizing its novel and proprietary BioErodible MucoAdhesive (BEMA) technology and other drug delivery technologies to develop and commercialize, either on its own or in partnership with third parties, new applications of therapies aimed at addressing important unmet medical needs. Its products include Belbuca and Symproic.

BioDelivery Sciences International (FRA:BD5) Headlines

No Headlines